A single-arm, phase II study of ipilimumab N01 in combination with sintilimab and a small-molecule tyrosine kinase inhibitor for the treatment of patients with hepatocellular carcinoma who have progressed after anti-PD-1/PD-L1 therapy combined with bevacizumab. (ChiCTR) - Oct 16, 2026 - P2 | N=50 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
New P2 trial • Hepatocellular Cancer • Oncology • Solid Tumor
|